Innovations

05/21/2021

Robert Fairchild, PhD - License of Urine Biomarker Test for Kidney Transplant Rejection

Robert Fairchild, PhD, joined Cleveland Clinic in 1990 after graduate education at Miami University and the University of Missouri and post-doctoral fellowships with the University of Colorado’s School of Medicine and the National Jewish Center for Immunology and Respiratory Medicine. Recruited to Cleveland Clinic to launch a transplant immunology research program, Dr. Fairchild brought with him extensive knowledge of chemokine production, leukocyte infiltration and their roles in immune response.

05/21/2021

Vince Tuohy, PhD – Development and License of Breast and Ovarian Cancer Vaccine Technologies

Appointed to Cleveland Clinic’s staff in 1989, inventor Vincent Tuohy, PhD, has a long history with autoimmune disease. Earning a PhD from the State University of New York and completing a fellowship in autoimmunity at Harvard Medical School, Dr. Tuohy developed an unusual and novel animal model for multiple sclerosis. Resulting in fame in the field, the model brought Dr. Tuohy to Cleveland Clinic’s Mellen Center, where his research focus would remain until 2002.

05/21/2021

Feng Lin, PhD – Development and Proof-of-Concept Testing of Humanized Antibody for Multiple Sclerosis

Complement biologist Feng Lin, PhD, brought his talents to Cleveland Clinic in 2013 after 15 years at Case Western Reserve University. Joining the Lerner Research Institute’s Inflammation and Immunity department, Dr. Lin continued his novel work with the Cluster of Differentiation 6 (CD6) gene and protein – his research focus for nearly a decade.

05/21/2021

Leveraging Small Company Business Funding to Advance Cleveland Clinic Technologies

Innovation at Cleveland Clinic and the Lerner Research Institute’s Office of Strategic Alliances and Technology Development established a new process to advance Cleveland Clinic technologies. The new process supports the formation of startup companies, a requirement to compete for over $2 billion in non-dilutive small business funding.

05/21/2021

Cleveland Clinic SPARK Program

In 2020, Lerner Research Institute’s Office of Strategic Alliances and Technology Development, with support from Innovation at Cleveland Clinic, created a new program to select and develop the enterprise’s most promising medical technologies. Following the SPARK Stanford model, this program supports technologies with significant clinical care impact, strong intellectual property positions and projected commercial returns. The program provides funding, mentorship and education and is sponsored by Amgen, AstraZeneca and ThermoFisher.

05/21/2021

Cleveland Clinic Center for Therapeutics Discovery (C3TD)

Last year, Cleveland Clinic’s Center for Therapeutics Discovery (C3TD) made significant advancements within a newly-renovated 6,000 sq. ft. laboratory to support chemistry and biology programs. This facility is equipped with 12 fume hoods, 3,600 square feet of bench space, a state-of-the-art nuclear magnetic resonance (NMR) facility, compound registration Dotmatics database, a Hamilton Verso storage system for libraries and final compounds, various purification systems and a liquid chromatography high-resolution mass spectrometry time-of-flight mass spectrometer.

05/21/2021

Eric Roselli, MD – Option of PHASTER Aortic Stent Graft Device

Eric Roselli, MD, Chief of Adult Cardiac Surgery and Director of the Aorta Center, came to Cleveland Clinic as an intern in 1997. Through his training in general and cardiothoracic surgery, Dr. Roselli had the opportunity to work with the late Roy Greenberg, MD, – a surgeon with whom he shared interests in treating complex aortic disease. Their partnership developed as Dr. Roselli honed his endovascular skills, which was a growing area. Dr. Roselli’s skills remain in heavy practice today, as he performs approximately 350 minimally invasive aortic valve repair, complex aorta operations and transcatheter procedures a year.

05/21/2021

Eric Yudelevich, MD & Andy Williams – GioBey Port Device: A Patient/Provider Collaboration

Eric Yudelevich, MD, is a Primary Care and Internal Medicine physician at Cleveland Clinic, joined the enterprise in 2017 after completing an Internal Medicine residency in New York City and medical school in Lomas Anahuac Mexico. Dr. Yudelevich has more than 11 years of diverse experience in the field. Through his practice, Dr. Yudelevich was introduced to Andrew Williams, a patient who would become a partner in the development of a technology now known as GioBey.

05/21/2021

Jacob Scott, MD, DPhil – Joint Development of PPE Sanitation Device Launching Startup CelerPurus

On March 22, 2020, Jacob Scott, MD, DPhil, Associate Staff with the Radiation Oncology and Translational Hematology & Oncology Research departments, returned from a run with an idea he thought might quell the personal protective equipment (PPE) usage concerns rapidly spreading through the country. A lab leader with access to biosafety cabinets, Dr. Scott hypothesized that the cabinets could be repurposed to decontaminate PPE. He called his lab team to campus to test this hypothesis.

05/21/2021

Douglas Johnston, MD – AR/VR: Training Up the Next-Gen Project

Douglas Johnston, MD, Vice-Chairman and Program Director of the Thoracic & Cardiovascular Surgery residency programs at Cleveland Clinic, joined the enterprise’s Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute nearly 13 years ago. After Harvard Medical School and residencies with Massachusetts General Hospital and Cleveland Clinic, Dr. Johnston was appointed at Cleveland Clinic in 2008. Today, Dr. Johnston leads the largest education program in the country for this specialty, where he and his colleagues train all stages of residents from all over the world.

< 1 2 >

Get In Touch With Us

Name

Ready to INVENT®? Download the Invention Disclosure Form Today.

Learn More

Save the Date for MIS2017: October 23-25 Genomics & Precision Medicine

Learn More